Concomitant glitazone or fenofibrate on outcomes of diabetic macular edema-patients taking ranibizumab

   Diana Do, MD, and colleagues at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, have found that the use of glitazone (GT) or fenofibrate (FF) did not appear to impact positive treatment outcomes in ranibizumab (RBZ)-treated patients with diabetic macular edema (DME).

   They investigated patients (0.3-mg RBZ, n=249; 0.5-mg RBZ, n=248) who did/did not receive concomitant GT or FF. They noted cases of BCVA, OCT, and diabetic retinopathy (DR) worsening at 24 months and made a comparison between patients who did/did not receive concomitant GT or FF therapy at any time during the 24-month trials.    

    Following data analysis, BCVA, OCT, and DR worsening did not differ significantly between patients taking GT (n=126) or FF (n=27) and patients who did not across RBZ-treated groups at 24 months (all P >/=0.05).